|
Composition:
Lamivudine
............................................................150
mg
Zidovudine USP
............................................................300
mg
Nevirapine
............................................................200
mg
Indications:
Dectrovir-N is indicated for the treatment of HIV
infection, once patients have been stabilized on the
maintenance regimen of nevirapine 200 mg bd, and
have demonstrated adequate tolerability to
nevirapine.
Description:
Nevirapine is a non-nucleoside reverse transcriptase
inhibitor (nNRTI) with activity against Human
Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and
eukaryotic DNA polymerases (such as human DNA
polymerases alpha, beta, or sigma) are not inhibited
by nevirapine. Nevirapine is, in general, only
prescribed after the immune system has declined and
infections have become evident. It is always taken
with at least one other HIV medication such as
Retrovir or Videx. The virus can develop resistance
to nevirapine if the drug is taken alone, although
even if used properly, nevirapine is effective for
only a limited time.
Nevirapine binds directly to reverse transcriptase (RT)
and blocks the RNA-dependent and DNA-dependent DNA
polymerase activities by causing a disruption of the
enzyme's catalytic site. The activity of nevirapine
does not compete with template or nucleoside
triphosphates.
Side
Effects
In
controlled clinical trials, the most common
Nevirapine
side
effect was rash, which in 7.6% of subjects was
considered severe. Increases in the liver enzymes
occurred in 5-10% of subjects compared with 2-5% in
controls.
CONTRAINDICATIONS:
Nevirapine is contraindicated in patients with clinically
significant hypersensitivity to any of the
components contained in the tablet or the oral
suspension.
Drug Interaction
Nevirapine is principally metabolized by the liver via the
cytochrome P450 isoenzymes, 3A4 and 2B6. Nevirapine
is known to be an inducer of these enzymes. As a
result, drugs that are metabolized by these enzyme
systems may have lower than expected plasma levels
when coadministered with nevirapine.
Dosage:
Adults: 1 tablet twice daily or as per the
physician’s advice.
Presentations:
30
tablets
MRP Retailer
Stockist
675.00
540.00
486.00
| 
